Favezelimab (Anti-LAG3 / CD223)
Favezelimab (Anti-LAG3 / CD223) (A2994-GRP)
Products
Description
Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2994 |
| Target | CD markers |